198 related articles for article (PubMed ID: 34108600)
1. RANKL immunisation inhibits prostate cancer metastasis by modulating EMT through a RANKL-dependent pathway.
Park M; Cho YJ; Kim B; Ko YJ; Jang Y; Moon YH; Hyun H; Lim W
Sci Rep; 2021 Jun; 11(1):12186. PubMed ID: 34108600
[TBL] [Abstract][Full Text] [Related]
2. Targeting IL-6 and RANKL signaling inhibits prostate cancer growth in bone.
Zheng Y; Basel D; Chow SO; Fong-Yee C; Kim S; Buttgereit F; Dunstan CR; Zhou H; Seibel MJ
Clin Exp Metastasis; 2014 Dec; 31(8):921-33. PubMed ID: 25223386
[TBL] [Abstract][Full Text] [Related]
3. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone metastasis via NF-κB signaling pathway.
Ren D; Yang Q; Dai Y; Guo W; Du H; Song L; Peng X
Mol Cancer; 2017 Jul; 16(1):117. PubMed ID: 28693582
[TBL] [Abstract][Full Text] [Related]
5. Activation of NF-κB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines.
Tsubaki M; Komai M; Fujimoto S; Itoh T; Imano M; Sakamoto K; Shimaoka H; Takeda T; Ogawa N; Mashimo K; Fujiwara D; Mukai J; Sakaguchi K; Satou T; Nishida S
J Exp Clin Cancer Res; 2013 Sep; 32(1):62. PubMed ID: 24011086
[TBL] [Abstract][Full Text] [Related]
6. Silibinin inhibits prostate cancer cells- and RANKL-induced osteoclastogenesis by targeting NFATc1, NF-κB, and AP-1 activation in RAW264.7 cells.
Kavitha CV; Deep G; Gangar SC; Jain AK; Agarwal C; Agarwal R
Mol Carcinog; 2014 Mar; 53(3):169-80. PubMed ID: 23115104
[TBL] [Abstract][Full Text] [Related]
7. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
8. RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization.
Chu GC; Zhau HE; Wang R; Rogatko A; Feng X; Zayzafoon M; Liu Y; Farach-Carson MC; You S; Kim J; Freeman MR; Chung LW
Endocr Relat Cancer; 2014 Apr; 21(2):311-26. PubMed ID: 24478054
[TBL] [Abstract][Full Text] [Related]
9. Arenobufagin inhibits prostate cancer epithelial-mesenchymal transition and metastasis by down-regulating β-catenin.
Chen L; Mai W; Chen M; Hu J; Zhuo Z; Lei X; Deng L; Liu J; Yao N; Huang M; Peng Y; Ye W; Zhang D
Pharmacol Res; 2017 Sep; 123():130-142. PubMed ID: 28712972
[TBL] [Abstract][Full Text] [Related]
10. Nimotuzumab inhibits epithelial-mesenchymal transition in prostate cancer by targeting the Akt/YB-1/AR axis.
Hu S; Duan YX; Zhou Q; Wang Y; Lu Q
IUBMB Life; 2019 Jul; 71(7):928-941. PubMed ID: 30907986
[TBL] [Abstract][Full Text] [Related]
11. Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells.
Odero-Marah VA; Wang R; Chu G; Zayzafoon M; Xu J; Shi C; Marshall FF; Zhau HE; Chung LW
Cell Res; 2008 Aug; 18(8):858-70. PubMed ID: 18645583
[TBL] [Abstract][Full Text] [Related]
12. Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis.
Li X; Liu Y; Wu B; Dong Z; Wang Y; Lu J; Shi P; Bai W; Wang Z
Oncol Rep; 2014 Dec; 32(6):2605-11. PubMed ID: 25333856
[TBL] [Abstract][Full Text] [Related]
13. Perillaldehyde inhibits bone metastasis and receptor activator of nuclear factor-κB ligand (RANKL) signaling-induced osteoclastogenesis in prostate cancer cell lines.
Lin Z; Huang S; LingHu X; Wang Y; Wang B; Zhong S; Xie S; Xu X; Yu A; Nagai A; Kobayashi Y; Wa Q; Huang S
Bioengineered; 2022 Feb; 13(2):2710-2719. PubMed ID: 34738877
[TBL] [Abstract][Full Text] [Related]
14. Prostaglandin E2 receptor EP4 is involved in the cell growth and invasion of prostate cancer via the cAMP‑PKA/PI3K‑Akt signaling pathway.
Xu S; Zhou W; Ge J; Zhang Z
Mol Med Rep; 2018 Mar; 17(3):4702-4712. PubMed ID: 29328471
[TBL] [Abstract][Full Text] [Related]
15. RANK/RANKL axis promotes migration, invasion, and metastasis of osteosarcoma via activating NF-κB pathway.
Takeda T; Tsubaki M; Genno S; Tomita K; Nishida S
Exp Cell Res; 2024 Mar; 436(2):113978. PubMed ID: 38382805
[TBL] [Abstract][Full Text] [Related]
16. Valproic acid (VPA) inhibits the epithelial-mesenchymal transition in prostate carcinoma via the dual suppression of SMAD4.
Lan X; Lu G; Yuan C; Mao S; Jiang W; Chen Y; Jin X; Xia Q
J Cancer Res Clin Oncol; 2016 Jan; 142(1):177-85. PubMed ID: 26206483
[TBL] [Abstract][Full Text] [Related]
17. Resveratrol induces depletion of TRAF6 and suppresses prostate cancer cell proliferation and migration.
Khusbu FY; Zhou X; Roy M; Chen FZ; Cao Q; Chen HC
Int J Biochem Cell Biol; 2020 Jan; 118():105644. PubMed ID: 31712163
[TBL] [Abstract][Full Text] [Related]
18. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.
Gravina GL; Mancini A; Muzi P; Ventura L; Biordi L; Ricevuto E; Pompili S; Mattei C; Di Cesare E; Jannini EA; Festuccia C
Prostate; 2015 Sep; 75(12):1227-46. PubMed ID: 26073897
[TBL] [Abstract][Full Text] [Related]
19. CCN3 promotes prostate cancer bone metastasis by modulating the tumor-bone microenvironment through RANKL-dependent pathway.
Chen PC; Cheng HC; Tang CH
Carcinogenesis; 2013 Jul; 34(7):1669-79. PubMed ID: 23536580
[TBL] [Abstract][Full Text] [Related]
20. Aphthous ulcer drug inhibits prostate tumor metastasis by targeting IKKɛ/TBK1/NF-κB signaling.
Cheng C; Ji Z; Sheng Y; Wang J; Sun Y; Zhao H; Li X; Wang X; He Y; Yao J; Wang L; Zhang C; Guo Y; Zhang J; Gao WQ; Zhu HH
Theranostics; 2018; 8(17):4633-4648. PubMed ID: 30279728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
